{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:57:00Z","timestamp":1776707820285,"version":"3.51.2"},"reference-count":7,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs). In this report, we describe the case of a female patient with metastatic lung adenocarcinoma, identified through NGS to carry a rare inverted SQSTM1-ALK (S5, A20) fusion. The patient received ensartinib as first-line therapy, resulting in a partial response (PR). At the time of publication, the patient\u2019s condition remained favorable. We have, for the first time, identified the presence of SQSTM1-ALK fusion in pericardial effusion, with the favorable response to ensartinib validating the oncogenic potential of SQSTM1-ALK fusion. The substantial advancements and extensive utilization of NGS have facilitated the identification of rare fusion variants.<\/jats:p>","DOI":"10.3389\/fphar.2024.1433894","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:43:22Z","timestamp":1730436202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Pandeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianji","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/PAS.0b013e318287791f","article-title":"STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target","volume":"37","author":"d\u2019Amore","year":"2013","journal-title":"Am. J. Surg. pathology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/modpathol.2017.191","article-title":"Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases","volume":"31","author":"Dickson","year":"2018","journal-title":"Mod. pathology official J. U. S. Can. Acad. Pathology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10637-019-00742-2","article-title":"Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report","volume":"37","author":"Honda","year":"2019","journal-title":"Investig. new drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-24-0231","article-title":"NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.21037\/jtd-23-380","article-title":"A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer","volume":"15","author":"Wang","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101560","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1433894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:43:24Z","timestamp":1730436204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1433894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":7,"alternative-id":["10.3389\/fphar.2024.1433894"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1433894","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"1433894"}}